Case Rep Womens Health The Use of Convalescent Plasma Therapy and Remdesivir in the Successful Management of a Critically Ill Obstetric Patient With Novel Coronavirus 2019 Infection: A Case Report

[tetano]

Case Rep Womens Health


. 2020 May 16;e00221.
doi: 10.1016/j.crwh.2020.e00221. Online ahead of print.
The Use of Convalescent Plasma Therapy and Remdesivir in the Successful Management of a Critically Ill Obstetric Patient With Novel Coronavirus 2019 Infection: A Case Report


Jonathon Anderson ¹ , Jordan Schauer ¹ , Suzanne Bryant ¹ , Cornelia R Graves ¹



Affiliations

• PMID: 32426243
• PMCID: PMC7229947
• DOI: 10.1016/j.crwh.2020.e00221

Abstract

Remdesivir is a novel therapeutic with known activity against SARS CoV-2 and related coronaviruses. Remdesivir, as well as convalescent plasma therapy, are currently under investigation as potential therapies for patients with Coronavirus Disease 19 (COVID-19). In this case report we summarize the use of convalescent plasma therapy and then remdesivir as a late addition in the treatment of a critically ill obstetric patient with COVID-19. The patient subsequently improved, was extubated 5 days after initiation of remdesivir, was transitioned to room air 24 h later, and discharged at the completion of remdesivir therapy.

Keywords: COVID-19; Convalescent plasma; Coronavirus; Pregnancy; Remdesivir; SARS CoV-2.